Biogen Denies Misleading Investors Over Alzheimer's Drug
Healthcare giant Biogen denied making any misleading statements to its investors Wednesday in a motion to dismiss a securities class action alleging the company knew an Alzheimer's drug was deficient but...To view the full article, register now.
Already a subscriber? Click here to view full article